Terguride in the treatment of Parkinson disease: preliminary experience.

Terguride, a partial DA-agonist with both dopaminergic and antidopaminergic properties, was tested in 11 PD patients in the "decompensated" phase of the disease, characterized by the presence of dyskinesias and motor fluctuations. Combined treatment of these patients with 1 mg/day of terguride and stabilized doses of levodopa reduced the severity and frequency of dyskinesias and motor fluctuations along with a slight but significant improvement of parkinsonian clinical picture. The "modulatory" effect of terguride on DA receptors, in this experimental conditions, is discussed.
AuthorsP Giovannini, I Piccolo, S Genitrini, F Girotti, D Testa, G Scigliano, I Suchy
JournalItalian journal of neurological sciences (Ital J Neurol Sci) Vol. 11 Issue 4 Pg. 381-5 (Aug 1990) ISSN: 0392-0461 [Print] ITALY
PMID2246121 (Publication Type: Journal Article)
Chemical References
  • dironyl
  • Levodopa
  • Lisuride
  • Dyskinesia, Drug-Induced (physiopathology)
  • Humans
  • Levodopa (adverse effects, therapeutic use)
  • Lisuride (analogs & derivatives, therapeutic use)
  • Male
  • Middle Aged
  • Parkinson Disease (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: